Singzyme
Abbas Sahili is an accomplished advisor and acting CEO at Singzyme since October 2022, where key contributions include being a founding team member and main co-inventor of core technology, drafting the initial business plan, and successfully leading fundraising efforts. Since October 2015, Abbas Sahili has served as a Senior Research Fellow at Nanyang Technological University, Singapore, leading research teams and authoring over 10 scientific papers focused on protein ligases and structural virology. Prior experience includes a role as Principal Scientist at Epitoire and a Ph.D. student at the Institute for Integrative Biology of the Cell, with a thesis centered on protein function and virulence. Educational qualifications comprise a Research Doctorate from Paris-Sud University and multiple degrees from Université de Lorraine, specializing in biochemistry and protein engineering.
This person is not in any teams
This person is not in any offices
Singzyme
Singzyme's mission is to deliver on the promise of effective immuno-therapies by developing safer and more homogenous, precision medicines for the well-being of patients worldwide. Singzyme applies its platform technology in the field of immuno-therapies with a focus on the conjugation of active molecules to protein carriers, for example, but not limited to Antibody-Drug Conjugates (ADCs). Singzyme provides an integrated, high-speed, precision bio-manufacturing platform for ADCs and other bioconjugates.